Open Menu Close Menu

Funding will be awarded to projects that improve the ability to enrich subject populations in clinical trials and/or determine whether experimental treatments are modifying the course of the disease, its symptoms or its progression. MJFF is also interested in supporting projects to determine target engagement/modulation and pharmacodynamic response, especially for high-priority therapeutic targets like alpha-synuclein, LRRK2, parkin and glucocerebrosidase.